Genitourinary oncology program

泌尿生殖系统（GU）癌症项目是一个跨学科小组，包括来自10个学术部门的成员：解剖学、生物化学与生物物理学、细胞与分子药理学、检验医学、医学、微生物学与免疫学、病理学、放射肿瘤学、放射学和泌尿学，共同研究膀胱癌、肾癌和前列腺癌。我们共同的兴趣是利用遗传、分子和细胞生物学的基础研究来了解泌尿生殖系统癌症的起源和发展机制，并利用这些知识来开发新的诊断和治疗方法。目前和正在发展的研究主要集中在前列腺癌诱导血管生成的分子病理学、前列腺癌中基质-上皮相互作用以及激素难治性前列腺癌（HRPC）的遗传基础。临床研究的主要焦点是在HRPC中使用免疫治疗和抗血管生成治疗，以及开发新的MRI/MRSI技术来评估前列腺癌。每月的项目会议是高度互动的，教师、博士后和研究生都参加得很好。从这些会议中，合作在几个层面上得到了发展和发展。几个NIH RO1资助和癌症PPG中的蛋白酶，以及CaP Cure临床研究的主要资助，为该计划提供了可观的资源。

Description: (Applicant's Description) The Genitourinary (GU) Cancer Program is an interdisciplinary group that includes members from 10 academic departments: Anatomy, Biochemistry & Biophysics, Cellular & Molecular Pharmacology, Laboratory Medicine, Medicine, Microbiology & Immunology, Pathology, Radiation Oncology, Radiology, and Urology working together on cancer of the bladder, kidney, and prostate. The common interest that spurred formation of this Program and fuels its existence is the utilization of basic research in genetic, molecular, and cellular biology to understand the origins and mechanisms of progression of genitourinary cancers, and to use this knowledge to develop novel approaches to their diagnosis and treatment. Current and developing research is focused on the molecular pathology of prostate cancer-induced angiogenesis, stromal-epithelial interactions in prostate cancer, and the genetic basis for hormone refractory prostate cancer (HRPC). Major foci in clinical research are the use of immunotherapy and anti-angiogenic treatments in HRPC, and developing novel MRI/MRSI technology for evaluating prostate cancer. Monthly Program conferences are highly interactive and very well attended by faculty, post-docs, and graduate students. From these meetings, collaborations have developed and grown at several levels. Several NIH RO1 grants and a Protease in Cancer PPG, as well as major grants from CaP Cure for clinical research, provide considerable resources for the Program.